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CO R R E S POND EN C E
The limitation of genetic testing in diagnosing patients
suspected for congenital platelet defects
To the Editor:
Congenital platelet defects (CPD) are rare disorders of primary
hemostasis caused by congenital defects in platelet production or func-
tion. Identification of CPDs is challenging due to the lack of awareness
resulting in late or missing referrals, the lack of diagnostic criteria,
absence or limitations of laboratory tests and poor standardization of
the available tests.1 However, an accurate diagnosis is important for
proper counseling and management of patients and to avoid ineffective
and potentially harmful treatments due to misdiagnosis, like idiopathic
thrombocytopenic purpura (ITP).
DNA-based analysis has become increasingly important for diag-
nosing CPDs.2 Genetic analysis can be useful to confirm a suspected
phenotypic diagnosis, and to identify patients with an increased risk
for associated pathologies, such as myelofibrosis (NBEAL2), renal
insufficiency (MYH9) and hematological malignancies (RUNX1). The
International Society for Thrombosis and Hemostasis (ISTH) currently
recommends to perform genetic analysis as a third-line investigation,
that is, after extensive phenotyping and functional analyses have con-
firmed the presence of a platelet disorder.3 Recent studies on the effi-
cacy of genetic testing in selected patients with platelet disorders
have suggested that genetic analysis could be moved “upward” in the
diagnostic approach in order to simplify and hasten the diagnosis of
CPDs.4-6 However, it remains unclear whether genetic analysis should
be performed as a first-line investigation, alongside initial functional
analysis of platelet function in unselected patients in whom a congeni-
tal platelet disorder is suspected.
In the Thrombocytopathy in the Netherlands (TiN) study, we
assessed the diagnostic value of genetic analysis performed in parallel
with routine laboratory tests in a prospective cohort of patients
suspected of having a CPD. Three categories of patients were
included in the study: (a) patients suspected of having a CPD based
on previous abnormal platelet counts, light transmission aggregometry
(LTA) results or platelet ADP content without a molecular diagnosis
(n = 96) (b) patients suspected of having a CPD based on a predomi-
nantly mucocutaneous bleeding tendency compatible with a CPD, in
whom other known causes of bleeding were excluded and in whom
previous LTA results were normal (n = 39), and (c) patients suspected
of having a CPD based on a predominantly mucocutaneous bleeding
tendency compatible with a CPD, in whom other known causes of
bleeding were excluded, newly referred for platelet function testing
(n = 21). Laboratory tests were performed for platelet count, aggrega-
tion response to four agonists, nucleotide content, surface receptor
expression with flow cytometry and whole-exome sequencing (WES)
with a selected 76 gene panel (Table S1). A CPD was diagnosed when
an abnormal platelet count or function was found on at least two sep-
arate occasions, of which one was in our diagnostic laboratory. A pos-
sible CPD was diagnosed when an abnormal platelet function was
found once in our diagnostic laboratory, or when abnormal platelet
function test results were inconsistent with previous findings. In line
with the American College of Medical Genetics guidelines, a genetic
variant was stated to be causal when a (likely) pathogenic variant
(class 4 or 5, respectively)7 was identified in one or more of the
selected genes that corresponded to the platelet phenotype.
In patients with previously abnormal laboratory results, a CPD was
confirmed in 61 of 96 (64%) patients, and a possible CPD was diag-
nosed in four of 96 (4%) patients. Eight of 96 (8%) patients received a
molecular diagnosis, and in 11 of 96 (11%) patients a variant of
unknown significance was identified (Table 1). In patients with previ-
ously normal LTA results and in newly referred patients, a possible CPD
was diagnosed in 10 of 39 (26%) and six of 21 (29%) patients, respec-
tively. No causal genetic variants were identified in these patients.
We included several subgroups of patients suspected of having a
CPD to properly assess when genetic analysis should be performed in
the diagnostic procedure. Our study shows that the diagnostic yield
of genetic analysis is limited in patients suspected for a CPD, since
only 5% (8/156) of patients received a molecular diagnosis. This is in
contrast to the diagnostic rate of 47.8% for platelet count defects,
and 26.1% for platelet function defects reported in a recent study.
There, 2396 patients with bleeding, thrombotic, and platelet disorders
(BTPD) were screened with a panel of 96 BTPD-associated genes, in
which the number of platelet associated genes was similar to our gene
panel.8 However, their diagnostic rate included variants of unknown
significance, resulting in an overestimation. Leaving out variants of
unknown significance strongly reduced the diagnostic rate. The differ-
ences between their and our study are also related to patient-selec-
tion. Our study reflects the real-life population of patients suspected
for a CPD referred to outpatient clinics of hemophilia treatment cen-
ters Their study included patients with a previously ascertained patho-
genic variant, or patients with phenotypes strongly indicative of a
particular disorder on the basis of laboratory abnormalities, with a
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high likelihood of having an inherited BTPD. In patients with either
normal laboratory assays or assays not diagnostic of an established
disorder, they reported a diagnostic rate of only 3.2%. Studies per-
formed in the Iberian Peninsula, with a gene panel similar to ours,
reported the identification of a molecular defect in 40%9 and 68%5 of
patients with (suspected) CPDs. Their studies included large numbers
of patients with Glanzmann thrombasthenia, Bernard-Soulier syn-
drome and MYH9-related disorders. Therefore, their study population
does not reflect clinical practice and is not comparable to ours. A
study performed in a pediatric population reported a positive molecu-
lar diagnosis in 23.8%.10 Their cohort included a relatively large num-
ber of patients with thrombocytopenia (67% vs 22% in our cohort)
and genetic testing was not performed as a first-line investigation.
It is possible that limitations of WES have led to an underestima-
tion of the number of patients with an identified genetic variant. First,
large insertions and deletions might be missed. Second, regulatory and
non-coding regions of the genome were not examined, and these
regions might harbor variants essential for controlling transcriptional
regulation or splicing. Third, by using a selected gene panel we might
have missed pathogenic variants in genes not included in the panel.
Finally, we cannot exclude that an additive effect of multiple genetic
variants that have escaped our selection, might underlie the CPD in
individual patients.
In conclusion, genetic testing with a selected gene panel has lim-
ited diagnostic yield in patients suspected for a CPD and should only
be performed in patients in whom a platelet number or function
defect is confirmed.
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